The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks fall after flat start

Fri, 09th Sep 2011 12:06

Stocks have eased slightly as nerves set in ahead of this weekend's meeting of the G7 grouping of industrialised countries.Motor insurer Admiral is in the slow lane after saying it could see "a small proportion" of its profits put at risk under the government's plans to ban the payment of referral fees to insurers. The Ministry of Justice (MoJ) announced that it plans to tackle rising insurance costs by placing abolishing the fees, as part of its commitment to curb 'compensation culture'. Referral fees account for 6% of Admiral's UK car insurance profit before tax.But Tullow Oil gushed higher after a joint venture it operates made an oil discovery at its Zeadyus exploration well, 150km offshore French Guiana. Shares surged over 8% in the opening minutes after its chief executive said, "The discovery at Zaedyus has proved the extension of the Jubilee-play across the Atlantic and made an important new discovery in French Guiana."Tullow owns 27.5% of the licence. North Petroleum and Wessex Exploration, which own 50% each of a joint venture with a 2.5% interest in the licence, have gushed higher. Shares of Investec edged higher after its announcement of a recommended offer for Evolution Securities, valuing the investment banking and stockbroking firm at £233.2m. Evolution's shares were given a boost early on.FTSE 250 oil and gas group Salamander Energy fell into the red after increasing its stake in Block G4/50, one of the largest blocks of prospective acreage in the Gulf of Thailand.Pubs group JD Wetherspoon saw shares drop after announcing that while like-for-like sales grew by 2.1% in the year to 24 July, the growth rate has slowed to 0.4% in the six weeks to 4 September.Multi-metal mining colossus Rio Tinto was lower after saying that it is to invest $310m to assure a sustainable water supply for its iron ore operations in Pilbara, Western Australia.FTSE 100 - RisersTullow Oil (TLW) 1,391.00p +13.37%Fresnillo (FRES) 2,194.00p +2.19%Imperial Tobacco Group (IMT) 2,096.00p +1.75%British Sky Broadcasting Group (BSY) 677.00p +1.20%Severn Trent (SVT) 1,472.00p +0.82%British Land Co (BLND) 525.00p +0.77%Next (NXT) 2,361.00p +0.55%British American Tobacco (BATS) 2,776.00p +0.49%Petrofac Ltd. (PFC) 1,391.00p +0.43%Morrison (Wm) Supermarkets (MRW) 302.80p +0.40%FTSE 100 - FallersLloyds Banking Group (LLOY) 30.99p -5.81%Royal Bank of Scotland Group (RBS) 21.58p -5.10%Admiral Group (ADM) 1,295.00p -5.06%Barclays (BARC) 151.50p -4.72%Xstrata (XTA) 1,006.00p -4.10%Glencore International (GLEN) 420.15p -3.75%International Consolidated Airlines Group SA (IAG) 156.40p -3.58%Vedanta Resources (VED) 1,402.00p -3.38%Aviva (AV.) 310.80p -3.12%GKN (GKN) 182.60p -2.98%FTSE 250 - RisersExillon Energy (EXI) 262.00p +13.76%Ocado Group (OCDO) 116.20p +7.10%JKX Oil & Gas (JKX) 183.10p +6.45%Imagination Technologies Group (IMG) 360.30p +4.43%EnQuest (ENQ) 106.40p +4.42%Kofax (KFX) 307.00p +2.68%Pennon Group (PNN) 672.00p +2.60%Hansteen Holdings (HSTN) 79.00p +2.60%ITE Group (ITE) 183.10p +2.29%AZ Electronic Materials SA (WI) (AZEM) 240.00p +2.04%FTSE 250 - FallersHome Retail Group (HOME) 110.80p -5.94%Enterprise Inns (ETI) 32.41p -4.48%Debenhams (DEB) 53.30p -4.39%New World Resources A Shares (NWR) 582.00p -4.35%JD Wetherspoon (JDW) 399.30p -4.01%Yule Catto & Co (YULC) 173.00p -4.00%SThree (STHR) 230.70p -3.92%Cookson Group (CKSN) 446.00p -3.78%Inchcape (INCH) 283.90p -3.76%Ferrexpo (FXPO) 368.00p -3.72%
More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.